Repare Therapeutics (RPTX) Projected to Post Quarterly Earnings on Thursday

Repare Therapeutics (NASDAQ:RPTX) will likely be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Repare Therapeutics to post earnings of ($0.49) per share and revenue of $7.50 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 13, 2025 at 7:00 AM ET.

Repare Therapeutics (NASDAQ:RPTX) last posted its earnings results on Friday, August 8th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.17. The business had revenue of $0.25 million during the quarter, compared to the consensus estimate of $2.50 million. On average, analysts expect Repare Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Repare Therapeutics Trading Down 1.4%

Repare Therapeutics stock opened at $1.81 on Tuesday. The company has a market capitalization of $77.93 million, a P/E ratio of -0.70 and a beta of 1.06. Repare Therapeutics has a 1-year low of $0.89 and a 1-year high of $4.07. The firm’s fifty day simple moving average is $1.78 and its 200-day simple moving average is $1.56.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on RPTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Repare Therapeutics in a research note on Wednesday, October 8th. HC Wainwright dropped their price objective on shares of Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Monday, October 27th. Finally, Wall Street Zen raised Repare Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $3.50.

Institutional Investors Weigh In On Repare Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. XTX Topco Ltd bought a new stake in Repare Therapeutics during the 2nd quarter worth about $60,000. Militia Capital Partners LP acquired a new stake in shares of Repare Therapeutics during the 2nd quarter worth approximately $166,000. Rangeley Capital LLC bought a new stake in shares of Repare Therapeutics during the second quarter worth approximately $494,000. Finally, Acadian Asset Management LLC grew its stake in shares of Repare Therapeutics by 35.6% during the first quarter. Acadian Asset Management LLC now owns 640,332 shares of the company’s stock worth $624,000 after purchasing an additional 168,230 shares during the period. Institutional investors own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.